Overview

* Sangamo Q3 2025 revenue misses analyst expectations, declining significantly from last year

* Net loss for Q3 2025 was $34.9 mln, compared to net income last year

* Company progresses Fabry disease program, preparing for BLA submission in 2026

Outlook

* Sangamo expects BLA submission for Fabry disease in Q1 2026

* Company plans CTA submission for prion disease by mid-2026

* Sangamo reiterates 2025 operating expenses guidance of $135 mln to $155 mln

Result Drivers

* NET LOSS - Consolidated net loss for the third quarter ended September 30, 2025 was $34.9 million, or $0.11 per share, compared to net income of $10.7 million, or $0.04 per share on a fully diluted basis, for the same period in 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $581,000 $34.40

Revenue mln (5

Analysts

)

Q3 Net -$34.93

Income mln

Q3 $33 mln

Adjusted

Operatin

g

Expenses

Q3 $36.10

Operatin mln

g

Expenses

Q3 -$35.55

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Sangamo Therapeutics Inc ( SGMO ) is $2.00, about 72.5% above its November 5 closing price of $0.55

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)